Juan C Almagro

This inventor holds 28 USPTO granted patents and 19 published patent applications and 2 EPO patents, primarily in Therapeutic Antibodies. Top assignees: Janssen Biotech, Inc., Arch Oncology, Inc., Pfizer Corporation. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juan C Almagro. Retrieved from https://idiyas.com/inventor/juan-c-almagro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 19)

% Patents Active = 85.7

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 7.3

ph-index = 7

Forward Citations = 118(Granted Patents)

Location History:

Radnor, PA (US) (2012 - 2015)
Boston, MA (US) (2015 - 2021)
Brookline, MA (US) (2013 - 2023)
Cambridge, MA (US) (2015 - 2024)

Company Filing History:

13 out of 435

Janssen Biotech, Inc.

The Brigham and Women's Hospital, Inc.

patents

5. 2 out of 31

Centocor Ortho Biotech Inc.

Eisai R&d Management Co., Ltd.

patents

8. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Interferon Beta Antibodies

CD73 Inhibitors

Anti-BCMA Antibodies

Therapeutic CD47 Antibodies

Human Oncostatin M Antibodies

Anti-CD27 Antibodies

IL-17A Antibodies

Engineered Anti-IL-13 Antibodies

Combination Therapy

Adenosine Receptor Inhibitors

Polynucleotides

Nucleic Acid Molecules

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448439 - Interferon beta antibodies and uses thereof (2025-10-21),

2. 12060433 - CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy (2024-08-13),

3. 12043670 - Anti-BCMA antibody-drug conjugates and methods of use (2024-07-23),

4. 12018089 - Anti-CD73 antibodies and uses thereof (2024-06-25),

5. 11858986 - Interferon beta antibodies and uses thereof (2024-01-02),

6. 11732050 - Neutralizing human anti-CD27 antibodies (2023-08-22),

7. 11692035 - Therapeutic CD47 antibodies (2023-07-04),

8. 11202828 - Therapeutic SIRP-α antibodies (2021-12-21),

9. 10941197 - Method of treating osteoarthritis with human oncostatin M antibodies (2021-03-09),

10. 10844124 - Therapeutic CD47 antibodies (2020-11-24),

11. 10829553 - Interferon beta antibodies and uses thereof (2020-11-10),

12. 10689453 - Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies (2020-06-23),

13. 10301392 - Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies (2019-05-28),

14. 10239945 - Therapeutic CD47 antibodies (2019-03-26),

15. 10179812 - Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies (2019-01-15),

Title: Juan C Almagro: Innovator in Antibody Therapeutics

Introduction

Juan C Almagro, located in Cambridge, MA, is a distinguished inventor with a notable portfolio of 25 patents in the field of biotechnology. His groundbreaking work primarily focuses on the development of therapeutic antibodies and their applications in treating various cancers.

Latest Patents

Among his recent patents, Almagro has developed innovative anti-BCMA antibody-drug conjugates and methods for their use. These antibodies and their conjugates target BCMA (B-cell maturation antigen), and the associated methods are significant for cancer treatment. Another noteworthy patent involves interferon beta antibodies, which bind specifically to interferon beta (IFNβ), enabling various therapeutic and diagnostic applications.

Career Highlights

Throughout his career, Almagro has made substantial contributions while working with prominent companies such as Janssen Biotech, Inc. and Arch Oncology, Inc. His expertise in antibody engineering has established him as a crucial figure in the development of next-generation cancer therapies.

Collaborations

Collaboration has been integral to Almagro's success. He has worked alongside notable colleagues, including Johan Fransson and Alexey Teplyakov, fostering innovation through shared knowledge and expertise in the field.

Conclusion

Juan C Almagro stands out as a prolific inventor whose work on antibody therapeutics holds great promise for advancing cancer treatment. His patents reflect a commitment to improving patient outcomes and demonstrate the impact of innovation in the biopharmaceutical industry.

Profile summary based on public USPTO records.